Space becomes testing ground for aging-disease research in orbit experiment

Orbital laboratories could unlock new insights into the protein abnormalities driving age-related diseases, as a British startup deploys its first experimental apparatus into space.

Mass Balance, a UK-based company, recently sent a small pod skyward aboard a SpaceX launch. The pocket-sized chamber—equipped with chemicals, sensors, and autonomous monitoring systems—will circle Earth for several weeks, collecting data on how living cells behave in the absence of gravity.

Why space matters for disease research#

On Earth, gravity constantly interferes with experiments studying certain molecules. Heat-driven circulation and the sinking of denser materials cloud measurements and distort results. Removing that gravitational pull opens new research possibilities, according to Mass Balance co-founder Toby Call: "When you take away gravity, a lot of weird and wonderful things happen, some of which will be very valuable for life sciences and pharma."

The company is particularly focused on disordered proteins—malformed molecules implicated in Alzheimer's, Parkinson's disease, and certain cancers. These proteins shift shape constantly under normal conditions, making them nearly impossible to image clearly or study systematically. That knowledge gap hampers AI protein-prediction systems like Google's AlphaFold, which lack training data on how these unstable proteins respond to potential medicines.

The business model#

Mass Balance's strategy involves running microgravity experiments to generate high-quality data on disordered proteins, then feeding that information into machine-learning models designed to predict protein behavior. The firm plans to monetize through data licensing and model access, rather than manufacturing products itself—a deliberate design choice that also eliminates the engineering headache of surviving atmospheric reentry.

Emerging orbital biotech sector#

Other companies are racing to develop space-based research platforms. British competitor BioOrbit recently tested equipment for growing ultra-pure crystals for cancer medicines, while American firm Varda Space Industries is exploring pharmaceutical production in orbit. Mass Balance's current mission represents an early validation phase; the pod will simply confirm that the autonomous system can track a chemical reaction reliably in zero gravity, using light sensors to monitor whether the expected breakdown occurs.

Call sees microgravity as an underutilized scientific tool. By making space "boring, reliable, and just another research environment," the company hopes to transform orbital laboratories from novelty into standard practice.